Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem
Weight Loss
A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At […]
As part of its ongoing RAK Weight Loss Challenge 2025, RAK Hospital hosted a deeply engaging and enlightening Obefit Webinar on “The Psychology of Weight Loss”, led by renowned clinical psychologist Dr. Savita Date. The session brought to light a powerful, often-overlooked truth: lasting weight loss begins in the mind, not just on the plate. […]
In a bid to support the community on their weight loss journey, RAK Hospital hosted an insightful and interactive session on sustainable weight management, as part of the 5th RAK Weight Loss Challenge 2025. Led by Ruba Elhourani, Senior Clinical Dietician and Head of Department at RAK Hospital, the session aimed to educate participants on […]
RAK Biggest Weight Loss Challenge 2024, a community initiative by RAK Hospital in collaboration with the Ministry of Health and Prevention Ras Al Khaimah, recently featured a compelling webinar shedding light on the intricate relationship between genetics and weight loss. Titled ‘Genetics: The Key to Your Unique Weight Loss Journey’, the session explored the














